Eloralintide
Metabolic
Also known as: LY3841136
Investigational, long-acting peptide and selective amylin receptor agonist (LY3841136), studied for obesity and weight management. A peer-reviewed phase 2 trial reported weight reduction over 48 weeks; phase 3 research is ongoing. Not an approved treatment; no self-use or dosing advice.
- Dose in studies
- No approved dose; no dosing recommendation provided.
- Frequency
- Once-weekly administration was investigated in clinical trials; not a use recommendation.
- Cycle length
- No established self-use cycle; the cited phase 2 observation lasted 48 weeks.
- Half-life
- Long-acting; no verified numerical human half-life added from the sources reviewed.
- Research level
- 3/5 – Moderate research
Frequently asked questions about Eloralintide
What is Eloralintide?
Investigational, long-acting peptide and selective amylin receptor agonist (LY3841136), studied for obesity and weight management. A peer-reviewed phase 2 trial reported weight reduction over 48 weeks; phase 3 research is ongoing. Not an approved treatment; no self-use or dosing advice.
What is the half-life of Eloralintide?
The half-life of Eloralintide is Long-acting; no verified numerical human half-life added from the sources reviewed..
What dosage of Eloralintide has been studied?
Described in research: No approved dose; no dosing recommendation provided., frequency: Once-weekly administration was investigated in clinical trials; not a use recommendation.. This is not a medical recommendation.
How long is a Eloralintide cycle?
Typical cycle length in studies: No established self-use cycle; the cited phase 2 observation lasted 48 weeks..
What are the side effects of Eloralintide?
Gastrointestinal adverse events, including nausea, and fatigue were reported in the phase 2 study. · Tolerability varied between trial regimens; this does not justify a self-directed escalation scheme. · The study size and duration do not exclude rare adverse events or establish long-term safety. · Pregnancy, breastfeeding, paediatric use and cancer-related safety are not established by the…
How well researched is Eloralintide?
Moderate research (3/5). Several controlled human studies or approval in a niche indication; evidence still patchy.
Sources (4)
- Billings LK et al. (2025) Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
- Eli Lilly and Company / ClinicalTrials.gov (2026) ENLIGHTEN-3: Eloralintide in obstructive sleep apnea and obesity or overweight (ongoing phase 3; no results)
- Eli Lilly and Company / ClinicalTrials.gov (2026) ENLIGHTEN-6: Eloralintide in persistent obesity on weekly incretin therapy (ongoing phase 3; no results)
- Lilly trial announcement (6 November 2025)